A small step toward precision dosing of caffeine in preterm infants: An external evaluation of published population pharmacokinetic models

被引:0
|
作者
Dai, Hao-Ran [1 ,2 ]
Liu, Yun [3 ]
Guo, Hong-Li [1 ]
Lu, Ke-Yu [3 ]
Hu, Ya-Hui [1 ]
Zhang, Yuan-Yuan [1 ]
Wang, Jie [1 ]
Ding, Xuan-Sheng [2 ]
Jiao, Zheng [4 ]
Cheng, Rui [3 ]
Chen, Feng [1 ]
机构
[1] Nanjing Med Univ, Pharmaceut Sci Res Ctr, Dept Pharm, Childrens Hosp, Nanjing 210008, Peoples R China
[2] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing 211198, Peoples R China
[3] Nanjing Med Univ, Childrens Hosp, Neonatal Intens Care Unit, Nanjing 210008, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pharm, Sch Med, 241 Huaihai West Rd, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
Caffeine; Preterm infants; Population pharmacokinetics; External evaluation; Model extrapolation; APNEA; THERAPY;
D O I
10.1016/j.ejpb.2024.114484
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Several population pharmacokinetic (PopPK) models of caffeine in preterm infants have been published, but the extrapolation of these models to facilitate model-informed precision dosing (MIPD) in clinical practice is uncertain. This study aimed to comprehensively evaluate their predictive performance using an external, independent dataset. Methods: Data used for external evaluation were based on an independent cohort of preterm infants. Currently available PopPK models for caffeine in preterm infants were identified and re-established. Prediction- and simulation-based diagnostics were used to assess model predictability. The influence of prior information was assessed using Bayesian forecasting. Results: 120 plasma samples from 76 preterm infants were included in the evaluation dataset. Twelve PopPK models of caffeine in preterm infants were re-established based on our previously published study. Although two models showed superior predictive performance, none of the 12 PopPK models met all the clinical acceptance criteria of these external evaluation items. Besides, the external predictive performances of most models were unsatisfactory in prediction- and simulation-based diagnostics. Nevertheless, the application of Bayesian forecasting significantly improved the predictive performance, even with only one prior observation. Conclusions: Two models that included the most covariates had the best predictive performance across all external assessments. Inclusion of different covariates, heterogeneity of preterm infant characteristics, and different study designs influenced predictive performance. Thorough evaluation is needed before these PopPK models can be implemented in clinical practice. The implementation of MIPD for caffeine in preterm infants could benefit from the combination of PopPK models and Bayesian forecasting as a helpful tool.
引用
收藏
页数:9
相关论文
共 49 条
  • [31] External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors
    Chen, Shengyang
    Huang, Lifeng
    Huang, Weikun
    Zheng, You
    Shen, Li
    Liu, Maobai
    Chen, Wansheng
    Wu, Xuemei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (04) : 437 - 448
  • [32] Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients
    Li, Xiping
    Liu, Xiaoqin
    Mao, Juehui
    Liu, Dong
    Jiao, Zheng
    PHARMACEUTICS, 2024, 16 (09)
  • [33] External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy
    Huang, Weikun
    Zheng, You
    Huang, Huiping
    Cheng, Yu
    Liu, Maobai
    Chaphekar, Nupur
    Wu, Xuemei
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (09) : 1447 - 1457
  • [34] External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy
    Weikun Huang
    You Zheng
    Huiping Huang
    Yu Cheng
    Maobai Liu
    Nupur Chaphekar
    Xuemei Wu
    European Journal of Clinical Pharmacology, 2022, 78 : 1447 - 1457
  • [35] External evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high-flux intermittent haemodialysis
    Ji, Cheng
    Garcia, Jonathan
    Sabuga, Argem Joy
    Ricard, Maurane
    Dion, France
    Rosu, Vlad Alexandru
    Legris, Marie-Eve
    Marsot, Amelie
    Nguyen, Van Dong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 91 (03) : 856 - 865
  • [36] External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model?
    Han, Lu
    Cui, Yifan
    Pan, Yan
    Chen, Rui
    Jiao, Zheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [37] External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients
    YL. Wang
    R. Guilhaumou
    O. Blin
    L. Velly
    Amélie Marsot
    European Journal of Clinical Pharmacology, 2020, 76 : 1281 - 1289
  • [38] External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients
    Wang, Y. L.
    Guilhaumou, R.
    Blin, O.
    Velly, L.
    Marsot, Amelie
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (09) : 1281 - 1289
  • [39] External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients
    Guo, Tingjie
    van Hest, Reinier M.
    Roggeveen, Luca F.
    Fleuren, Lucas M.
    Thoral, Patrick J.
    Bosman, Rob J.
    van der Voort, Peter H. J.
    Girbes, Armand R. J.
    Mathot, Ron A. A.
    Elbers, Paul W. G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [40] External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
    Schraepel, Christina
    Kovar, Lukas
    Selzer, Dominik
    Hofmann, Ute
    Tran, Florian
    Reinisch, Walter
    Schwab, Matthias
    Lehr, Thorsten
    PHARMACEUTICS, 2021, 13 (09)